Patient groups rank Lundbeck first in corporate reputation

DEERFIELD - Lundbeck US, an affiliate of Danish-based H. Lundbeck A/S, ranked first in corporate reputation among 30 U.S. pharmaceutical companies for the second year in a row, according to patient groups in PatientView's 5th annual Corporate Reputation of Pharma study.

For the second consecutive year, Lundbeck also ranked first in all seven indicators of corporate reputation.

"At Lundbeck, we truly believe success starts and ends with reputation, particularly in our patient communities, so we are thrilled to receive this positive recognition from advocacy organizations that represent the patients we serve," said Peter Anastasiou, President of Lundbeck North America. "We value our relationships with patient groups tremendously so to receive this accolade in two consecutive years is humbling and will continue to fuel our mission of improving the lives of patients with debilitating brain diseases."

PatientView's study reflects the views of 164 U.S. patient groups on seven key reputational attributes: Patient-Centricity, Information, Patient Safety, Usefulness of Products, Transparency, Integrity and Patient Group Relationships.

Among the report's highlights:

• 64.3 percent of respondents familiar with Lundbeck US identified the company as having the "most effective patient-centered strategy" (21 percent ahead of the second highest ranked organization)

• 42.3 percent of respondents familiar with Lundbeck US identified the company as having the "most integrity" (13 percent ahead of the second highest ranked organization)

• 69.2 percent of the patient groups familiar with Lundbeck US selected

Lundbeck US as the company with the best patient-group relationships (19 percent ahead of the second highest ranked organization)

Lundbeck's deep engagement with patient organizations goes beyond its products and involves active participation in patient communities by hundreds of employees. In fact, last year alone, the company's employees led or participated in close to 600 initiatives in support of patient communities. Ongoing engagements include programs to support employers and community-based organizations in efforts to address individuals with mental illness, scholarship programs for patients and caregivers to attend educational conferences, volunteerism at hundreds of local nonprofit events and an art therapy program for people with epilepsy called Studio E.

"We have been working with Lundbeck for many years and truly value their partnership," said Elizabeth "Eli" Pollard, Executive Director at the World Parkinson Coalition. "In our collaborations with Lundbeck, we have found their commitment to patients runs deep, thanks to their dedication to advocacy work at the grass-roots level in communities around the country. At a corporate level, they truly rely on our insights and advice to help advance their work for people living with Parkinson's disease and other challenging brain disorders. We are lucky to have them on the Parkinson's team."

The PatientView survey was fielded between November 2016 and February 2017 and included 52 groups that address Lundbeck's core area of focus: brain disorders (43 patient groups specializing in neurological diseases and 9 specializing in mental health). The study includes a mix of global, international, national, large regional and local patient groups.